Atlas Antibodies Acquires evitria
July 28, 2021
Atlas Antibodies, majority owned by Patricia Industries, has agreed to acquire evitria, a Zurich-based specialist in transient recombinant antibody expression in CHO cells. Sellers include Afinum and co-investor SHS Capital; the deal is expected to close in Q3 2021 and is positioned as an add-on to build an antibody-focused platform under Patricia Industries.
- Buyers
- Atlas Antibodies, Patricia Industries
- Targets
- evitria
- Sellers
- Afinum, SHS Capital
- Platforms
- Atlas Antibodies
- Industry
- Biotechnology
- Location
- Zurich, Switzerland
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
AVS Bio Acquires ImmunoPrecise Antibodies (Europe) B.V.
August 6, 2025
Biotechnology
AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies (Europe) B.V., a carve-out from ImmunoPrecise Antibodies Ltd. The acquisition expands AVS Bio's European footprint and adds antibody discovery, recombinant protein expression, and organoid growth factor development capabilities to its biologics services platform.
-
Atlas Antibodies Acquires HistoCyte Laboratories Ltd
February 1, 2021
Medical Devices
Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
Valerio Therapeutics Acquires Emglev Therapeutics
September 29, 2024
Biotechnology
Valerio Therapeutics S.A. completed the acquisition of Emglev Therapeutics on September 29, 2024, transferring Emglev's proprietary synthetic single-domain antibody (sdAb) platform into a newly formed Valerio subsidiary, Valour Bio. The deal was structured as a cash sale of shares combined with a contribution-in-kind (Emglev shares exchanged for Valour Bio shares), making Emglev shareholders shareholders of Valour Bio and positioning Valour Bio to advance sdAb discovery and development across oncology and inflammatory/autoimmune indications.
-
Twist Bioscience Acquires Abveris
November 22, 2021
Biotechnology
Twist Bioscience entered into a definitive agreement to acquire Abveris (formerly AbX Biologics), an in vivo antibody discovery services company, for up to $190 million. The deal (approximately $150 million at closing in Twist common stock and up to $40 million contingent stock consideration plus limited cash) is intended to combine Abveris's mouse-based discovery platform with Twist's humanization and antibody engineering capabilities to broaden Twist's antibody discovery and biopharma services.
-
Epsilogen Acquires TigaTx to Create Pan-Isotype Cancer Antibody Company
April 7, 2025
Biotechnology
Epsilogen Ltd has completed the acquisition of Boston-based TigaTx, Inc., making TigaTx a wholly owned subsidiary. The deal combines TigaTx's engineered IgA antibody assets with Epsilogen's IgE capabilities to build a pan-isotype oncology antibody company and broaden the combined clinical-stage pipeline.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.